Sleep Medications: Where They Fit, and Where They Do Not

Physician Article Dr. Brian Harris
Sleep Medications: Where They Fit, and Where They Do Not
Why this matters

The most common mistake with sleep medication is not using it—it is expecting it to solve the wrong problem. Medication can be useful tonight, but insomnia is not a single problem, and sleep medications are not a single category. Sedation is easy to mistake for treatment, but they are not the same thing.

In plain language

There are many different types of "sleeping pills," and they all work differently.

  • The "Better" Options: Medications like low-dose doxepin or newer "orexin antagonists" (like Belsomra or Dayvigo) are often safer for long-term use because they have a lower risk of dependence.
  • The "Careful" Options: Familiar drugs like Xanax or Ambien can help in a crisis, but using them every night can lead to tolerance (they stop working) and a difficult time stopping later.
  • The "Avoid" Options: Using strong antipsychotics (like Seroquel) or old-school antihistamines (like Benadryl) *just* for sleep is often a poor trade-off due to side effects like morning fogginess or long-term cognitive risks.

Medication should be used as "scaffolding" while you do the real work of fixing your sleep habits, not as the entire plan.

Clinical deep dive

Pharmacotherapy in sleep medicine should be intentional, targeted, and time-limited where possible. For chronic insomnia, CBT-I is the first-line treatment; medications are adjunctive.

Categories of Sleep Pharmacotherapy

1. DORAs (Dual Orexin Receptor Antagonists): (e.g., Suvorexant, Lemborexant). These block the "wake" signal (hypocretin/orexin) rather than broadly sedating the brain. They have a favorable profile for both sleep onset and maintenance with low abuse potential. 2. Hypnosedatives (Benzodiazepines & Z-drugs): (e.g., Temazepam, Zolpidem). These modulate GABA receptors. While effective for acute SOL reduction, they carry risks of tolerance, dependence, complex sleep behaviors, and cognitive impairment in elderly populations (Beers Criteria). 3. Melatonin Receptor Agonists: (e.g., Ramelteon). Useful for sleep-onset insomnia and circadian misalignment, with minimal risk of dependence. 4. Sedating Antidepressants: (e.g., Low-dose Doxepin, Trazodone). Doxepin is FDA-approved specifically for sleep maintenance at very low doses (3–6mg) where it acts as a selective H1 antagonist.

The "Off-Label" Trap

Using neuroleptics (e.g., Quetiapine) for primary insomnia is generally discouraged by the AASM and APA unless a comorbid psychiatric condition exists. The risk of metabolic syndrome, tardive dyskinesia, and daytime sedation often outweighs the marginal sleep benefit in non-psychotic populations.